XORTX to focus on late stage allopurinol intolerant gout program; discussion with FDA planned for first half 2025 regarding NDA filing CALGARY, Alberta, Jan. 06, 2025 (GLOBE NEWSWIRE) -- XORTX ...

XORTX to focus on late stage allopurinol intolerant gout program; discussion with FDA planned for first half 2025 regarding NDA filing We apologize, but this video has failed to load. Try refreshing ...